Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
Using Genotype-Tissue Expression project samples, researchers put together gene regulatory networks for 29 tissue types, uncovering extensive sex-related regulatory differences.
The Bay Area startup is offering a no-touch method to separate cell populations for downstream analysis in genomics and synthetic biology applications.
The firm said its test is one-thousandfold more sensitive than conventional SARS-CoV-2 serology tests and could enable earlier antibody detection in patients.
The biobank will collect samples and data from Biogen employees who contracted and have recovered from COVID-19, as well as their family members and close contacts.
Using systems biology, investigators put cancer risk SNPs in a network context, identifying immune, tumor-related, and other genes influenced by the variants in multiple tissue types.
